Argenx SE (ARGX)
argenx develops antibody medicines for autoimmune and neuromuscular diseases, with its main product VYVGART. It last closed at $925.70 on Nov 20, down 1.73% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From ARGX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 19). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on ARGX
Technical AnalysisPrices may be delayed
The stock sits between its 20 and 50 day averages. It is 7% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 50). The nearest support is the 100 day average at $925.02, and the nearest resistance the 20 day average at $926.20.
| RSI (14) | 49.95 | Middle of its range | Neutral |
| MACD | 12.65 | Above its signal line | Bullish |
| Stochastic | 54.7 | Middle of its range | Neutral |
| ADX (14) | 18.8 | No clear trend | |
| Williams %R | -54.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 15.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −0.2% | Change over 10 sessions | Bearish |
| ATR (14) | $26.87 | Typical daily range, 2.9% of price |
| RSI (14) | 52.96 | Middle of its range | Neutral |
| MACD | 17.12 | Below its signal line | Bearish |
| Stochastic | 52.6 | Middle of its range | Neutral |
| ADX (14) | 21.2 | Weak trend | |
| Williams %R | -51.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 25.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −6.0% | Change over 10 sessions | Bearish |
| ATR (14) | $68.99 | Typical daily range, 7.5% of price |
What happened before
See how ARGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options FlowPrices may be delayed
90DNo whale options trades in ARGX in the last 90 days.
Dark PoolPrices may be delayed
30DARGX Institutional Ownership
Full report →- ▲313 buying vs 192 selling
- ●Shares held by funds -0.9%
- ▲Funds holding +42
- ▲Superinvestors: 4 added, 0 cut
- ▼Put/call 0.14 to 0.74
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 555 | 513 | +8.2% |
| In funds' top 10 | 14 | 13 | +7.7% |
| Held by funds | – | – | – |
| New / increased | 90 / 223 | 81 / 179 | +20.4% |
| Reduced / sold out | 144 / 48 | 164 / 50 | −10.3% |
| Put/call ratio | 0.74 | 0.14 | +427.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARGX is in one of them and how their past ARGX trades turned out.
ARGX News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARGX in an article yet. Here's the latest on the wider market.
ARGX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Oct 27, 2026 | Nov 10, 2026 | 14 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Oct 15, 2026 | Nov 10, 2026 | 26 d |
| Gilbert CisnerosD · CA | Buy | $15K – $50K | Oct 14, 2026 | Nov 10, 2026 | 27 d |
| Alan ArmstrongR · OK | Buy | $1K – $15K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Dan GoldmanD · NY | Sell | $1K – $15K | Jul 10, 2023 | Aug 13, 2023 | 34 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Argenx SE
argenx is a biopharmaceutical company that develops antibody medicines for autoimmune and neuromuscular diseases. Its main product, VYVGART, is approved for several conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The company sells its medicines to patients and works with healthcare professionals, and it is developing a range of other candidates in clinical trials. It is based in Zwijnaarde.
- Headquarters
- Zwijnaarde






